vs

Side-by-side financial comparison of EverQuote, Inc. (EVER) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $195.3M, roughly 1.1× EverQuote, Inc.). EverQuote, Inc. runs the higher net margin — 29.6% vs -62.0%, a 91.6% gap on every dollar of revenue. On growth, EverQuote, Inc. posted the faster year-over-year revenue change (32.5% vs 25.9%). EverQuote, Inc. produced more free cash flow last quarter ($25.8M vs $-100.8M). Over the past eight quarters, EverQuote, Inc.'s revenue compounded faster (46.5% CAGR vs 38.0%).

EverQuote, Inc. is an online insurance marketplace founded in 2011 and based in Cambridge, Massachusetts.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

EVER vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.1× larger
RARE
$207.3M
$195.3M
EVER
Growing faster (revenue YoY)
EVER
EVER
+6.6% gap
EVER
32.5%
25.9%
RARE
Higher net margin
EVER
EVER
91.6% more per $
EVER
29.6%
-62.0%
RARE
More free cash flow
EVER
EVER
$126.6M more FCF
EVER
$25.8M
$-100.8M
RARE
Faster 2-yr revenue CAGR
EVER
EVER
Annualised
EVER
46.5%
38.0%
RARE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EVER
EVER
RARE
RARE
Revenue
$195.3M
$207.3M
Net Profit
$57.8M
$-128.6M
Gross Margin
97.7%
Operating Margin
9.5%
-54.7%
Net Margin
29.6%
-62.0%
Revenue YoY
32.5%
25.9%
Net Profit YoY
369.3%
3.5%
EPS (diluted)
$1.53
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EVER
EVER
RARE
RARE
Q4 25
$195.3M
$207.3M
Q3 25
$173.9M
$159.9M
Q2 25
$156.6M
$166.5M
Q1 25
$166.6M
$139.3M
Q4 24
$147.5M
$164.6M
Q3 24
$144.5M
$139.5M
Q2 24
$117.1M
$147.0M
Q1 24
$91.1M
$108.8M
Net Profit
EVER
EVER
RARE
RARE
Q4 25
$57.8M
$-128.6M
Q3 25
$18.9M
$-180.4M
Q2 25
$14.7M
$-115.0M
Q1 25
$8.0M
$-151.1M
Q4 24
$12.3M
$-133.2M
Q3 24
$11.6M
$-133.5M
Q2 24
$6.4M
$-131.6M
Q1 24
$1.9M
$-170.7M
Gross Margin
EVER
EVER
RARE
RARE
Q4 25
97.7%
Q3 25
97.3%
Q2 25
96.9%
Q1 25
96.8%
Q4 24
96.3%
Q3 24
96.2%
Q2 24
95.7%
Q1 24
94.5%
Operating Margin
EVER
EVER
RARE
RARE
Q4 25
9.5%
-54.7%
Q3 25
10.1%
-106.9%
Q2 25
9.0%
-64.8%
Q1 25
4.8%
-102.6%
Q4 24
8.2%
-74.3%
Q3 24
8.1%
-94.6%
Q2 24
5.4%
-79.1%
Q1 24
1.9%
-151.9%
Net Margin
EVER
EVER
RARE
RARE
Q4 25
29.6%
-62.0%
Q3 25
10.8%
-112.8%
Q2 25
9.4%
-69.0%
Q1 25
4.8%
-108.5%
Q4 24
8.3%
-80.9%
Q3 24
8.0%
-95.7%
Q2 24
5.5%
-89.5%
Q1 24
2.1%
-156.8%
EPS (diluted)
EVER
EVER
RARE
RARE
Q4 25
$1.53
$-1.28
Q3 25
$0.50
$-1.81
Q2 25
$0.39
$-1.17
Q1 25
$0.21
$-1.57
Q4 24
$0.35
$-1.34
Q3 24
$0.31
$-1.40
Q2 24
$0.17
$-1.52
Q1 24
$0.05
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EVER
EVER
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$171.4M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$238.0M
$-80.0M
Total Assets
$326.9M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EVER
EVER
RARE
RARE
Q4 25
$171.4M
$421.0M
Q3 25
$145.8M
$202.5M
Q2 25
$148.2M
$176.3M
Q1 25
$125.0M
$127.1M
Q4 24
$102.1M
$174.0M
Q3 24
$82.8M
$150.6M
Q2 24
$60.9M
$480.7M
Q1 24
$48.6M
$112.3M
Stockholders' Equity
EVER
EVER
RARE
RARE
Q4 25
$238.0M
$-80.0M
Q3 25
$174.9M
$9.2M
Q2 25
$170.3M
$151.3M
Q1 25
$149.5M
$144.2M
Q4 24
$135.4M
$255.0M
Q3 24
$117.7M
$346.8M
Q2 24
$100.8M
$432.4M
Q1 24
$88.3M
$140.3M
Total Assets
EVER
EVER
RARE
RARE
Q4 25
$326.9M
$1.5B
Q3 25
$256.1M
$1.2B
Q2 25
$241.4M
$1.3B
Q1 25
$232.1M
$1.3B
Q4 24
$210.5M
$1.5B
Q3 24
$180.5M
$1.5B
Q2 24
$158.0M
$1.6B
Q1 24
$135.4M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EVER
EVER
RARE
RARE
Operating Cash FlowLast quarter
$27.0M
$-99.8M
Free Cash FlowOCF − Capex
$25.8M
$-100.8M
FCF MarginFCF / Revenue
13.2%
-48.6%
Capex IntensityCapex / Revenue
0.6%
0.5%
Cash ConversionOCF / Net Profit
0.47×
TTM Free Cash FlowTrailing 4 quarters
$90.3M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EVER
EVER
RARE
RARE
Q4 25
$27.0M
$-99.8M
Q3 25
$19.8M
$-91.4M
Q2 25
$25.3M
$-108.3M
Q1 25
$23.3M
$-166.5M
Q4 24
$20.1M
$-79.3M
Q3 24
$23.6M
$-67.0M
Q2 24
$12.4M
$-77.0M
Q1 24
$10.4M
$-190.7M
Free Cash Flow
EVER
EVER
RARE
RARE
Q4 25
$25.8M
$-100.8M
Q3 25
$18.5M
$-92.7M
Q2 25
$23.8M
$-110.7M
Q1 25
$22.2M
$-167.8M
Q4 24
$19.1M
$-79.5M
Q3 24
$22.1M
$-68.6M
Q2 24
$11.5M
$-79.0M
Q1 24
$9.7M
$-193.9M
FCF Margin
EVER
EVER
RARE
RARE
Q4 25
13.2%
-48.6%
Q3 25
10.6%
-58.0%
Q2 25
15.2%
-66.5%
Q1 25
13.3%
-120.5%
Q4 24
13.0%
-48.3%
Q3 24
15.3%
-49.2%
Q2 24
9.8%
-53.7%
Q1 24
10.6%
-178.2%
Capex Intensity
EVER
EVER
RARE
RARE
Q4 25
0.6%
0.5%
Q3 25
0.7%
0.8%
Q2 25
0.9%
1.5%
Q1 25
0.7%
1.0%
Q4 24
0.7%
0.1%
Q3 24
1.0%
1.2%
Q2 24
0.7%
1.4%
Q1 24
0.8%
3.0%
Cash Conversion
EVER
EVER
RARE
RARE
Q4 25
0.47×
Q3 25
1.05×
Q2 25
1.72×
Q1 25
2.92×
Q4 24
1.64×
Q3 24
2.04×
Q2 24
1.93×
Q1 24
5.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EVER
EVER

Automotive$179.9M92%
Home And Renters$15.4M8%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons